Mary Ann Liebert: Complement System Response to AAV Vector Gene Therapy
February 23, 2024
February 23, 2024
NEW ROCHELLE, New York, Feb. 23 -- Mary Ann Liebert Inc. issued the following news release:
Recent clinical trials utilizing high doses of adeno-associated virus (AAV) vectors have highlighted a new challenge to AAV gene transfer - activation of the complement system. A new article in the peer-reviewed journal Human Gene Therapy describes how a convergence of AAV-specific, environmental, and patient-specific factors shaping complement responses likely contribute to differential outc . . .
Recent clinical trials utilizing high doses of adeno-associated virus (AAV) vectors have highlighted a new challenge to AAV gene transfer - activation of the complement system. A new article in the peer-reviewed journal Human Gene Therapy describes how a convergence of AAV-specific, environmental, and patient-specific factors shaping complement responses likely contribute to differential outc . . .